Aptamers as a promising approach for the control of parasitic diseases

Juan David Ospina-Villa, Absalom Zamorano-Carrillo, Carlos A. Castañón-Sánchez, Esther Ramírez-Moreno, Laurence A. Marchat

Research output: Contribution to journalShort survey

3 Citations (Scopus)

Abstract

© 2016 Sociedade Brasileira de Infectologia Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensitivity, minimize duration and cost of the assay, as well as increase target types. Several biochemical modifications can help to enhance aptamer stability without affecting significantly target interaction. As a result, aptamers have generated a large interest as promising tools to compete with monoclonal antibodies for detection and inhibition of specific markers of human diseases. One aptamer-based drug is currently authorized and several others are being clinically evaluated. Despite advances in the knowledge of parasite biology and host–parasite interactions from “omics” data, protozoan parasites still affect millions of people around the world and there is an urgent need for drug target discovery and novel therapeutic concepts. In this context, aptamers represent promising tools for pathogen identification and control. Recent studies have reported the identification of “aptasensors” for parasite diagnosis, and “intramers” targeting intracellular proteins. Here we discuss various strategies that have been employed for intracellular expression of aptamers and expansion of their possible application, and propose that they may be suitable for the clinical use of aptamers in parasitic infections.
Original languageAmerican English
Pages (from-to)610-618
Number of pages9
JournalBrazilian Journal of Infectious Diseases
DOIs
StatePublished - 1 Nov 2016

Fingerprint

Parasitic Diseases
Parasites
SELEX Aptamer Technique
Single-Stranded DNA
Protein Transport
Drug Discovery
Oligonucleotides
Monoclonal Antibodies
RNA
Costs and Cost Analysis
Pharmaceutical Preparations
Therapeutics

Cite this

Ospina-Villa, Juan David ; Zamorano-Carrillo, Absalom ; Castañón-Sánchez, Carlos A. ; Ramírez-Moreno, Esther ; Marchat, Laurence A. / Aptamers as a promising approach for the control of parasitic diseases. In: Brazilian Journal of Infectious Diseases. 2016 ; pp. 610-618.
@article{490c6372017e41d792b07d3550c82476,
title = "Aptamers as a promising approach for the control of parasitic diseases",
abstract = "{\circledC} 2016 Sociedade Brasileira de Infectologia Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensitivity, minimize duration and cost of the assay, as well as increase target types. Several biochemical modifications can help to enhance aptamer stability without affecting significantly target interaction. As a result, aptamers have generated a large interest as promising tools to compete with monoclonal antibodies for detection and inhibition of specific markers of human diseases. One aptamer-based drug is currently authorized and several others are being clinically evaluated. Despite advances in the knowledge of parasite biology and host–parasite interactions from “omics” data, protozoan parasites still affect millions of people around the world and there is an urgent need for drug target discovery and novel therapeutic concepts. In this context, aptamers represent promising tools for pathogen identification and control. Recent studies have reported the identification of “aptasensors” for parasite diagnosis, and “intramers” targeting intracellular proteins. Here we discuss various strategies that have been employed for intracellular expression of aptamers and expansion of their possible application, and propose that they may be suitable for the clinical use of aptamers in parasitic infections.",
author = "Ospina-Villa, {Juan David} and Absalom Zamorano-Carrillo and Casta{\~n}{\'o}n-S{\'a}nchez, {Carlos A.} and Esther Ram{\'i}rez-Moreno and Marchat, {Laurence A.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bjid.2016.08.011",
language = "American English",
pages = "610--618",
journal = "Brazilian Journal of Infectious Diseases",
issn = "1413-8670",
publisher = "Elsevier Editora Ltda",

}

Aptamers as a promising approach for the control of parasitic diseases. / Ospina-Villa, Juan David; Zamorano-Carrillo, Absalom; Castañón-Sánchez, Carlos A.; Ramírez-Moreno, Esther; Marchat, Laurence A.

In: Brazilian Journal of Infectious Diseases, 01.11.2016, p. 610-618.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Aptamers as a promising approach for the control of parasitic diseases

AU - Ospina-Villa, Juan David

AU - Zamorano-Carrillo, Absalom

AU - Castañón-Sánchez, Carlos A.

AU - Ramírez-Moreno, Esther

AU - Marchat, Laurence A.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - © 2016 Sociedade Brasileira de Infectologia Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensitivity, minimize duration and cost of the assay, as well as increase target types. Several biochemical modifications can help to enhance aptamer stability without affecting significantly target interaction. As a result, aptamers have generated a large interest as promising tools to compete with monoclonal antibodies for detection and inhibition of specific markers of human diseases. One aptamer-based drug is currently authorized and several others are being clinically evaluated. Despite advances in the knowledge of parasite biology and host–parasite interactions from “omics” data, protozoan parasites still affect millions of people around the world and there is an urgent need for drug target discovery and novel therapeutic concepts. In this context, aptamers represent promising tools for pathogen identification and control. Recent studies have reported the identification of “aptasensors” for parasite diagnosis, and “intramers” targeting intracellular proteins. Here we discuss various strategies that have been employed for intracellular expression of aptamers and expansion of their possible application, and propose that they may be suitable for the clinical use of aptamers in parasitic infections.

AB - © 2016 Sociedade Brasileira de Infectologia Aptamers are short single-stranded RNA or DNA oligonucleotides that are capable of binding various biological targets with high affinity and specificity. Their identification initially relies on a molecular process named SELEX (Systematic Evolution of Ligands by EXponential enrichment) that has been later modified in order to improve aptamer sensitivity, minimize duration and cost of the assay, as well as increase target types. Several biochemical modifications can help to enhance aptamer stability without affecting significantly target interaction. As a result, aptamers have generated a large interest as promising tools to compete with monoclonal antibodies for detection and inhibition of specific markers of human diseases. One aptamer-based drug is currently authorized and several others are being clinically evaluated. Despite advances in the knowledge of parasite biology and host–parasite interactions from “omics” data, protozoan parasites still affect millions of people around the world and there is an urgent need for drug target discovery and novel therapeutic concepts. In this context, aptamers represent promising tools for pathogen identification and control. Recent studies have reported the identification of “aptasensors” for parasite diagnosis, and “intramers” targeting intracellular proteins. Here we discuss various strategies that have been employed for intracellular expression of aptamers and expansion of their possible application, and propose that they may be suitable for the clinical use of aptamers in parasitic infections.

U2 - 10.1016/j.bjid.2016.08.011

DO - 10.1016/j.bjid.2016.08.011

M3 - Short survey

C2 - 27755981

SP - 610

EP - 618

JO - Brazilian Journal of Infectious Diseases

JF - Brazilian Journal of Infectious Diseases

SN - 1413-8670

ER -